logo
Plus   Neg
Share
Email

ImaginAb, AstraZeneca, Pfizer, Takeda Join To Develop CD8 ImmunoPET Technology

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announced Monday that it has signed a multi-party collaboration deal with AstraZeneca Plc (AZN.L,AZN), Pfizer Inc. (PFE) and Takeda Pharmaceutical Co. Ltd. The agreement is focused on furthering the clinical development of ImaginAb's CD8 ImmunoPET technology.

Under the deal terms, the collaborators will help guide a current ImaginAb-sponsored clinical trial that aims to evaluate the utility and value of CD8 ImmunoPET in immuno-oncology drug development.

In return, the collaborators will gain early access to clinical and imaging data and collectively contribute to the post-trial data analysis.

The ImmunoPET technology uses ImaginAb's 'Minibody' platform, and targets and visualizes CD8+ T cells to provide highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient. This helps to tailor treatment quickly and specifically to the needs of that patient.

Ian Wilson, Chief Executive Officer of ImaginAb, said, " We believe that working with global leaders in immuno-oncology will help us further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development and, in the future, as a diagnostic and predictive test for use in hospitals."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford plans to bring back the Bronco as a dedicated off-road brand when it launches an all-new 4x4 SUV lineup on July 13. The automaker said it will introduce an all-new Bronco brand under the tagline, "Built Wild". The new lineup includes two-door and four-door models of the Bronco as well as the Bronco Sport compact SUV. J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles.
Follow RTT